Merck Announces Third-Quarter 2022 Financial Results

Go back to Merck Announces Third-Quarter 2022 Financial Results

Merck (MRK) PT Raised to $120 at Cantor Fitzgerald

October 27, 2022 12:47 PM EDT

Cantor Fitzgerald analyst Louise Chen raised the price target on Merck (NYSE: MRK) to $120.00 (from $107.00) while maintaining an Overweight rating.

The analyst commented, ". Post a 3Q22 sales and EPS beat relative to FactSet consensus, we are reiterating our Overweight (OW) rating. We are... More

Merck (MRK) Tops Q3 EPS by 10c

October 27, 2022 6:33 AM EDT

Merck (NYSE: MRK) reported Q3 EPS of $1.85, $0.10 better than the analyst estimate of $1.75. Revenue for the quarter came in at $15 billion versus the consensus estimate of $14.07 billion.

GUIDANCE:

Merck sees FY2022 EPS of $7.32-$7.35, versus the consensus of $7.34. Merck sees... More